Publication at First Faculty of Medicine, Third Faculty of Medicine |
2010
Abstract
Antithrombotic therapy plays an important role in the prophylaxis of cardiovascular disease. Over the recent years, we have been witnessing an arrival of new antiplatelet therapies.
A number of new antibody-based molecules inhibiting thrombocyte adhesion are at the stage of clinical evaluation. Similarly, we see the new platelet P2Y12 receptor antagonists (prasugrel, ticagrelor, cangrelor, elinogrel), thromboxane receptor antagonists (terutroban) or PAR 1-type thrombin receptor antagonists (SCH 530348).
Some from within this array of drugs, e.g. prasugrel, have now been released for clinical use, while others have just entered the clinical testing stage.